TXNIP and non-alcoholic fatty liver: Rapamycin (a thioredoxin interacting protein (TXNIP) agonist) treatment also attenuated MCD-induced steatosis, inflammation, and fibrosis with increased TFEB nuclear translocation and restored FAO in TXNIP-KO mice by inhibiting MTORC1 to promote autophagy.330 Despite the positive preclinical results, more clinical studies should be conducted to verify the efficacy of apoptosis inhibitors in the treatment of patients with NAFL/NASH.